STAT1 min read
STAT+: Pharmalittle: Investors Reject Proposals For Covid Vaccine Makers To Share Know-how; CMS Head Says Alzheimer’s Drug Decision Is Rare
CMS head Chiquita Brooks-LaSure says the agency expects to keep covering drugs that the FDA approves through its fast-track accelerated approval pathway, despite its recent decision on Biogen's Aduhelm.
STAT1 min read
STAT+: Pharmalittle: Amgen Faces $7B IRS Back-tax Bill And Fine; McKinsey Exec Apologizes For Opioid Work During Hearing
The top executive at McKinsey appeared for the first time before Congress to answer for the consulting firm’s role in fanning the opioid crisis.
STAT1 min read
STAT+: Pharmalittle: J&J Sues Wholesalers And A Pharmacy Over Fake HIV Meds; Rite Aid To Pay $123 Million To Humana For Inflating Drug Prices
Rite Aid was ordered to pay nearly $123 million to Humana for allegedly seeking inflated reimbursements for prescription drugs.
STAT1 min read
STAT+: Pharmalittle: White House Announces Covid-pill Push; ‘Right-to-try’ Think Tank Is Back With A New Law
The Biden administration announced a series of initiatives aimed at increasing the use of antiviral pills to treat Covid-19, with a focus on Pfizer's Paxlovid.
STAT1 min read
STAT+: Pharmalittle: Are New ADHD Treatments Really Any Better? India Moves To Reduce Dependence On China For Pharma Ingredients
Parents and doctors now have more tools than ever to help kids manage symptoms of ADHD. But are these new drugs and devices any better than what’s come before?
STAT1 min read
STAT+: Pharmalittle: U.S. Health Agency Workers Fail To Report Political Interference; Canada Walks Back Some Drug-pricing Reforms
Staff at U.S. health agencies fail to report suspected political interference that is inappropriately influencing government policymaking.
STAT1 min read
STAT+: Pharmalittle: U.S. Spending On Medicines Rose 12% Last Year; Louisiana Sues A PBM For Allegedly Overcharging
Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as usage reached record levels and new prescriptions largely recovered from the pandemic slowdown.
STAT1 min read
STAT+: Pharmalittle: Glaxo Workers In The U.K. Vote To Strike; Alabama Reaches $276 Million Deal Over Opioid Crisis
Several hundred GlaxoSmithKline workers have voted to go on strike after rejecting a below-inflation pay raise, setting the stage for a labor battle unusual in the pharmaceutical industry.
STAT1 min read
STAT+: Pharmalittle: Global Demand For Pfizer Covid-19 Pill Falls; Biotech Hub In Massachusetts Set For A Correction
Worldwide demand for the Pfizer Covid-19 antiviral pill has been unexpectedly light due to eligibility requirements, reduced testing, and potential drug interactions.
STAT1 min read
STAT+: Pharmalittle: U.K Watchdog Agency Is Urged To Bolster Conflicts Policy; FDA Device Program Helps Makers More Than Patients
The U.K. medicines watchdog agency is being urged to strengthen its conflict of interest policy after it was disclosed that six of its board members are receiving payments from pharma…
STAT1 min readInternational Relations
STAT+: Pharmalittle: WTO Head Says Covid Vaccine IP Talks Are Nearing Agreement; RSV Is The Next Big Target For Vaccine Makers
The head of the World Trade Organization says negotiations on an intellectual property proposal for Covid-19 vaccines are "trying to iron out the last things."
STAT1 min read
STAT+: Pharmalittle: Justice Department Probes Bausch Over Marketing; Pfizer To Seek Covid Booster For Healthy 5- To 11-year-olds
Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines used to treat skin conditions.
STAT1 min read
STAT+: Pharmalittle: U.K. Advances Novel Payment System For Antibiotics; Glaxo To Pay $1.9 Billion For Sierra Oncology
Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming the first country to launch an experimental payment model for antibiotics.
STAT1 min read
STAT+: Pharmalittle: Will Biogen Sue CMS Over Alzheimer’s Drug Coverage? Novartis Plans To Lay Off Thousands
Biogen and other drugmakers have already hinted they might sue Medicare over its decision to limit coverage for the controversial new Alzheimer's drug Aduhelm.
STAT1 min read
STAT+: Pharmalittle: Lilly And Eisai Will Still Seek Accelerated Approval For Alzheimer’s Drugs; CAR-T Cells May Shrink Some Solid Tumors
Eisai and Eli Lilly still plan to seek accelerated approval for Alzheimer's drugs even after CMS severely limited coverage of medicines approved under the controversial program.
STAT1 min read
STAT+: Pharmalittle: Medicare Finalizes Plan For Controversial Alzheimer’s Drug; Advocacy Group Faces Controversy Over CMS Proposal
Medicare finalized its plan to restrict coverage for the controversial, pricey Alzheimer’s treatment Aduhelm to patients participating in clinical trials.
STAT1 min read
STAT+: Pharmalittle: Low-income Part D Beneficiaries Without Subsidies Often Don’t Fill Scripts; Pfizer Strikes A Deal For RSV Drugs
Many lower-income Medicare Part D beneficiaries who do not receive subsidies — which can cap or lower out-of-pocket costs — did not fill their prescriptions.
STAT1 min read
STAT+: Pharmalittle: Most Americans Would Get A Second Booster Shot; FDA Pulls Glaxo Covid Treatment
A new survey by STAT and The Harris Poll finds 6 in 10 Americans have already decided they will get another Covid booster shot if it’s recommended for them.
STAT1 min read
STAT+: Pharmalittle: Bluebird Axes Nearly One-third Of Its Employees; Senate Committee Probes Merck’s Tax Practices
Bluebird Bio is reducing expenses and laying off nearly a third of its employees to preserve cash ahead of two pivotal gene-therapy approval decisions expected later this year.
STAT1 min read
STAT+: Pharmalittle: Novartis Reorganizes And Hopes To Save $1 Billion; Industry-backed Antibiotic Fund Makes First Investments
Novartis is simplifying its structure as part of plans to save $1 billion in costs by 2024 and strengthen its business in the U.S.
STAT1 min readAmerican Government
Opinion: Narrowing The Vaccine Gap As Boosters Begin For People Over 50
Among those over 50, 15% aren't fully vaccinated and 50% haven't received a booster. Protecting those at greatest risk requires more federal funding.
STAT1 min read
STAT+: Pharmalittle: Califf Admits Alzheimer’s Drug Controversy Has Hurt Expert Trust In FDA; House Passes Bill To Lower Insulin Costs
In advance of a World Health Assembly meeting, the U.K. is circulating a resolution that outlines goals for improving clinical trials quality.
STAT1 min read
STAT+: Pharmalittle: Roche Immunotherapy Fails Its First Test; Key U.S. Senators Move Closer To Bill To Cap Insulin Prices
Roche disclosed that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer.
STAT1 min read
STAT+: Pharmalittle: Pfizer Employees Balk At Returning Overpayments; Biogen Stops Work On Another ALS Drug
Pfizer employees are frustrated and angry over a payroll mistake that could force them to give back money some have already spent.
STAT1 min read
STAT+: Pharmalittle: Pharma Showers Cash On A Rising U.S. Senate Star; FDA Restricts Use Of A Glaxo Covid Treatment
U.S. Sen. Tim Scott of South Carolina, a rising star in the Republican Party, is getting showered with pharmaceutical industry money before facing voters this fall.
STAT1 min read
STAT+: Pharmalittle: Pharma Hunts For A Cure For Long Covid; Texas AG Deepens Puberty-blocker Probe Into AbbVie And Endo
Researchers and drugmakers are turning to finding a cure for long Covid, a more elusive target than vaccines and treatments for acute infection.
STAT1 min read
STAT+: Pharmalittle: FDA Rejects Lilly Drug Studied Only In China; AstraZeneca Suffers A Setback With A Key Cancer Drug
The Food and Drug Administration declined to approve an Eli Lilly (LLY) lung cancer drug that had been studied only in China.
STAT1 min read
STAT+: Pharmalittle: Moderna Asks FDA To OK Covid Shot For Kids Under 6; Big Generic Maker To Close U.S. Plant
Moderna will ask the U.S. Food and Drug Administration to authorize its Covid-19 vaccine for emergency use in children aged 6 months to 6 years.
STAT1 min read
STAT+: Pharmalittle: FDA Faces Immense Pressure Over An ALS Drug; Former Biogen R&D Chief Seeks A Reset At Another Biotech
Al Sandrock, the top Biogen scientist who exited last year in a dispute over its controversial Alzheimer’s drug, was named CEO of Voyager Therapeutics.
STAT1 min read
STAT+: Pharmalittle: Covid-19 Vaccine Market Is Getting Crowded As Demand Wanes; Russia Looks To India To Supply Pharmaceuticals
The prospects for would-be Covid-19 vaccine manufacturers to prove their shots are protective are becoming ever slimmer.
…Or Discover Something New